Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 3.90B |
| Revenue (ttm) | 116.10M |
| Net Income (ttm) | 1.59B |
| Shares Out | 69.54M |
| EPS (ttm) | 22.93 |
| PE Ratio | 2.43 |
| Forward PE | 2.47 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $55.79 |
| Previous Close | $55.10 |
| Change ($) | 0.69 |
| Change (%) | 1.25% |
| Day's Open | 55.56 |
| Day's Range | 55.21 - 56.69 |
| Day's Volume | 529,317 |
| 52-Week Range | 32.47 - 58.93 |
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that ...
Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that ...
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year.
– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease –
– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announ...
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today annou...
– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) –
– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission in Q1 2021 –
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 –
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announ...
Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals under its...
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Investors applauded the company's planned sale of its oncology portfolio.
The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.
Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical company. S...
– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to...
– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced tha...
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced th...
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.
– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –
Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced tha...
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced th...
Agios: A Look At Mitapivat In Anaemia, Its Backup Indication
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.
Agios: A Look At TIBSOVO In CC Patients
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
– Supplemental New Drug Application Planned f or Submission in Q1 2021 –
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2013 |
| CEO Jacqualyn Fouse | Employees 562 |
| Stock Exchange NASDAQ | Ticker Symbol AGIO |
Financial Performance
In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.
Analyst Forecasts
According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 64.88, which is an increase of 16.29% from the latest price.